Patents Assigned to Amgen Inc.
  • Self-buffering antibody formulations
    Patent number: 11607451
    Abstract: The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use. The self-buffering protein formulations are substantially free of other buffering agents, stably maintain pH for the extended time periods involved in the distribution and storage of pharmaceutical proteins for veterinary and human medical use. The invention further provides methods for designing, making, and using the formulation. In addition to other advantages, the formulations avoid the disadvantages associated with the buffering agents conventionally used in current formulations of proteins for pharmaceutical use.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: March 21, 2023
    Assignee: Amgen Inc.
    Inventors: Yatin R. Gokarn, Eva Kras, Richard Louis Remmele, Jr., David Brems, Susan Irene Hershenson
  • RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
    Publication number: 20230078200
    Abstract: The present invention relates to RNAi constructs for reducing expression of the LPA gene, which encodes apolipoprotein(a), a component of lipoprotein(a) (Lp(a)) particles. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease, peripheral artery disease, stroke, and myocardial infarction, and to reduce serum Lp(a) levels are also described.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 16, 2023
    Applicant: AMGEN INC.
    Inventors: Bin WU, Michael OLLMANN, Oliver HOMANN, Yuan CHENG
  • Methods for increasing mannose content of recombinant proteins
    Patent number: 11597959
    Abstract: The present invention relates to methods of upregulating the high mannose glycoform content of a recombinant protein during a mammalian cell culture by manipulating the mannose to total hexose ratio in the cell culture media formulation.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: March 7, 2023
    Assignee: Amgen Inc.
    Inventors: Chung-Jr Huang, Xiaoming Yang
  • Sheet lighting for particle detection in drug product containers
    Patent number: 11592403
    Abstract: In a method for imaging a container holding a sample, the container is illuminated with a laser sheet that impinges upon the container in a first direction corresponding to a first axis. A plane of the laser sheet is defined by the first axis and a second axis orthogonal to the first axis. The method also includes capturing, by a camera having an imaging axis that is substantially orthogonal to at least the first axis, an image of the container. The method further includes analyzing, by one or more processors, the image of the container to detect particles within, and/or on an exterior surface of, the container.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: February 28, 2023
    Assignee: AMGEN INC.
    Inventors: Thomas Clark Pearson, Graham F. Milne, Dmitry Fradkin, Erwin Freund
  • Syringe assembly for a drug delivery device and method of assembly
    Patent number: 11590294
    Abstract: A syringe assembly for a drug delivery device. The syringe assembly includes a syringe barrel having a proximal end, a distal end, and a longitudinal axis. A needle assembly is operatively coupled to the syringe barrel and includes a needle hub and a needle attached to the needle hub. A flexible connection is disposed between the syringe barrel and the needle hub and forms a fluid pathway between the syringe barrel and the needle. The flexible connection enables the needle assembly to be moveable from a filling position, in which a longitudinal axis of the needle assembly is parallel to a longitudinal axis of the syringe barrel, to an assembled position, in which the longitudinal axis of the needle assembly is not parallel to the longitudinal axis of the syringe barrel.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: February 28, 2023
    Assignee: AMGEN INC.
    Inventors: Adam B. McCullough, Hans Stenberg Knudsen, Rasmus Øhlenschlæger
  • Drug delivery device with activation prevention feature
    Patent number: 11590277
    Abstract: A wearable drug delivery device includes an injector having a housing, a reservoir, a needle or cannula, a drive mechanism for urging drug product out of the reservoir, through the needle or cannula, and to a patient, and an activator mechanism disposed on a surface of the housing for activating the drive mechanism. An activation prevention mechanism is coupled to the injector housing and/or activation prevention mechanism to prevent inadvertent actuation of the activator mechanism.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: February 28, 2023
    Assignee: AMGEN INC.
    Inventors: Brian Stonecipher, Margaux Frances Boyaval, James Chan, Avon Kuo, Allan Lee Cameron, Maxwell Franklin Bischoff, Gregg Allen Flender
  • ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF
    Publication number: 20230059353
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Application
    Filed: March 4, 2022
    Publication date: February 23, 2023
    Applicants: DAIICHI SANKYO EUROPE GMBH, AMGEN INC.
    Inventors: MIKE ROTHE, MARTIN TREDER, ERIC BORGES, LARRY GREEN, SUSANNE HARTMANN
  • Systems and methods for delayed drug delivery
    Patent number: 11583633
    Abstract: Systems and methods for delayed delivery of a drug are disclosed. A drug delivery system may include a delivery member for insertion into a patient and a reservoir configured to receive a volume of a drug. An energy source may be activatable by the patient to actuate the reservoir to deliver the drug to the patient as a single bolus. A lockout system may be configured to have a locked state, wherein the lockout system prevents movement of the delivery member and/or activation of the energy source, and an unlocked state, wherein the lockout system permits movement of the delivery member and/or activation of the energy source. The lockout system may be configured to automatically change from the locked state to the unlocked state after a preselected time period has elapsed. An output element may generate a detectable output after the preselected time period has elapsed for notifying the patient.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: February 21, 2023
    Assignee: AMGEN INC.
    Inventors: Scott Robert Gibson, Adam B. McCullough
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20230052348
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 16, 2023
    Applicant: AMGEN INC.
    Inventors: Sean P BROWN, David Karl BEDKE, Michael R. DEGRAFFENREID, Jiasheng FU, Zhinghong LI, Felix GONZALEZ LOPEZ DE TURISO, Ana GONZALEZ BUENROSTRO, Michael W. GRIBBLE JR., Michael G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Mario G. CARDOZO, Alan C. CHENG
  • DIRECT SELECTION OF CELLS EXPRESSING HIGH LEVELS OF HETEROMERIC PROTEINS USING GLUTAMINE SYNTHETASE INTRAGENIC COMPLEMENTATION VECTORS
    Publication number: 20230048658
    Abstract: This invention relates to the general field of recombinant expression of polypeptides in animal cell culture. More specifically, the invention concerns improved selection of cells transfected with recombinantly engineered vectors designed to express polypeptides, in particular heteromultimeric polypeptides.
    Type: Application
    Filed: May 26, 2022
    Publication date: February 16, 2023
    Applicant: AMGEN INC.
    Inventors: Trent P. MUNRO, Neeraj Jagdish AGRAWAL, Kristine M. DARIS
  • Methods of treating heart failure with cardiac sarcomere activators
    Patent number: 11576910
    Abstract: Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: February 14, 2023
    Assignees: AMGEN INC., CYTOKINETICS, INC.
    Inventors: Narimon Honarpour, Fady Malik
  • Method for making injectable pharmaceutical compositions
    Patent number: 11576856
    Abstract: The invention relates to methods for making injectable pharmaceutical compositions wherein particles present in the compositions are detected and analyzed, and the acceptance of the compositions is determined based on chemical and physical properties as well as toxicology and patient risks associated of the particles.
    Type: Grant
    Filed: April 2, 2019
    Date of Patent: February 14, 2023
    Assignee: AMGEN INC.
    Inventors: Andrew Phillip Spasoff, Susanne Therese Atkinson, Adrian Bennis, Erwin Freund
  • INTERLEUKIN-2 IN COMBINATION WITH TNF RECEPTOR FAMILY MEMBERS FOR THE EXPANSION OF T-REGULATORY CELLS
    Publication number: 20230040604
    Abstract: Provided herein are combinations of an IL-2 molecule or mutein and a TNFR agonist, and complexes comprising IL-2/TNFR agonist molecules, such as Fc-bound IL-2/TNFR agonist molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are methods of making and using the compositions of the present invention.
    Type: Application
    Filed: December 17, 2020
    Publication date: February 9, 2023
    Applicant: AMGEN INC.
    Inventors: Ashutosh CHAUDHRY, Wenjun OUYANG
  • N-cyano-7-azanorbornane derivatives and uses thereof
    Patent number: 11572374
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: February 7, 2023
    Assignee: AMGEN INC.
    Inventors: John R. Butler, Daniel Erlanson, Russell Graceffa, Jeffrey Iwig, Joon Won Jeong, Ryan D. White, Yongwei Wu, Shuyan Yi, Xiao Mei Zheng, Jesse M. McFarland, Abhisek Banerjee
  • Insertion mechanism and method of inserting a needle of a drug delivery device
    Patent number: 11571511
    Abstract: An insertion mechanism for a drug delivery device. The insertion mechanism includes a proximal end, a distal end, a first opening disposed near the proximal end, and a second opening disposed in the distal end. A needle or cannula assembly is disposed within a housing and has a base with a proximal surface and a distal surface and a needle or cannula coupled to the distal surface. A retraction member is disposed within the housing to maintain the needle or cannula assembly in a retracted position before movement to an extended position, the retraction member in contact with the base. Upon supplying pressure through the first opening until an amount of pressure P1 applies an application force to the proximal surface of the base that surpasses a resistive force of the retraction member, the needle or cannula assembly is moved from the retracted position to the extended position.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: February 7, 2023
    Assignee: AMGEN INC.
    Inventor: Adam B. McCullough
  • Systems and approaches for sterilizing a drug delivery device
    Patent number: 11565006
    Abstract: An on-body injector system includes a drug container assembly including a container, a seal member, and a sealing interface between the seal member and the container. The container includes an opening and the seal member at least partially covers the opening in the container. A fluid pathway assembly is coupled to the drug container assembly and includes a needle that is movable between a storage position, in which a point of the needle is spaced from the seal member, and a delivery position, in which the point of the needle is disposed at least partially through the seal member. A radiation generator is configured to emit rays of radiation to sterilize and/or disinfect the sealing interface. A barrier is disposed adjacent to the sealing interface and has an opening. At least a portion of the drug container assembly is positioned adjacent to the opening in the barrier.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: January 31, 2023
    Assignee: AMGEN INC.
    Inventors: Loic Barbedette, Shaun Devitt, Wael Mismar
  • VEGFR-FC FUSION PROTEIN FORMULATIONS
    Publication number: 20230025418
    Abstract: VEGFR-Fc fusion protein formulations and methods of making using such formulations are provided herein. In one embodiment, the formulation is an ophthalmic formulation, such as for intravitreal administration. In some embodiments, the VEGFR-Fc fusion protein is aflibercept.
    Type: Application
    Filed: September 14, 2022
    Publication date: January 26, 2023
    Applicant: Amgen Inc.
    Inventors: Yael WEXLER-COHEN, Robert Matthew FESINMEYER, Monica Michelle GOSS, Sekhar KANAPURAM, Rahul Rajan KAUSHIK, Sai Chakradhar PADALA
  • Method of promoting regulatory T-cell proliferation
    Patent number: 11560415
    Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: January 24, 2023
    Assignee: AMGEN INC.
    Inventors: Marc A. Gavin, Li Li
  • Capture Purification Processes for Proteins Expressed in a Non-Mammalian System
    Publication number: 20230016430
    Abstract: Methods of purifying proteins expressed in non-mammalian expression systems in a non-native soluble form directly from cell lysate are disclosed. Methods of purifying proteins expressed in non-mammalian expression systems in a non-native limited solubility form directly from a refold solution are also disclosed. Resin regeneration methods are also provided.
    Type: Application
    Filed: July 27, 2022
    Publication date: January 19, 2023
    Applicant: AMGEN INC.
    Inventors: Joseph Edward SHULTZ, Roger HART
  • METHODS FOR TREATING OR PREVENTING MIGRAINE HEADACHE
    Publication number: 20230020514
    Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.
    Type: Application
    Filed: September 2, 2022
    Publication date: January 19, 2023
    Applicant: AMGEN INC.
    Inventors: Hong SUN, Eduardo DUNAYEVICH, Robert A. LENZ, Gabriel VARGAS